Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed ...

We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...

Personalis (PSNL) and Tempus AI (TEM) announced that the companies have expanded their commercial relationship.The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD ...

Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...

Tempus AI, Inc. Class A ((TEM)) has held its Q1 earnings call. Read on for the main highlights of the call. Tempus AI’s latest earnings call painted a picture of a company balancing rapid growth with ...

CHICAGO--(BUSINESS WIRE)-- Northwestern Medicine and Tempus AI, Inc. (TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide ...

Tempus AI, once boosted by Nancy Pelosi’s investment disclosure, has seen its stock fall nearly 50% from a $100 peak despite strong revenue growth. The company reports Q1 results tomorrow, with ...

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million, while ...

In the first earnings call since Tempus AI became a public company, founder and CEO Eric Lefkofsky said strong second-quarter financials came out with "everything the way you want to see it." The ...

Tempus AI’s TEM strategic focus for 2026 centers on expanding its AI-driven precision medicine platform by scaling the diagnostics business, growing data and AI capabilities and strengthening ...